Comparator supply for NCT05564390
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Sponsor: National Cancer Institute (NCI) (NIH). Phase: PHASE2. Status: Recruiting. Countries: United States, Canada, Puerto Rico. Last update posted 2026-10-21.
Registry record: https://clinicaltrials.gov/study/NCT05564390.
Canadian-labelled azacitidine
7 marketed Canadian product(s) from 5 manufacturer(s) contain azacitidine. Available strengths: 100 MG, 200 MG, 300 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled busulfan
3 marketed Canadian product(s) from 3 manufacturer(s) contain busulfan. Available strengths: 2 MG, 6 MG, 60 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled cytarabine
3 marketed Canadian product(s) from 3 manufacturer(s) contain cytarabine. Available strengths: 100 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled cytarabine and daunorubicin liposomal
3 marketed Canadian product(s) from 3 manufacturer(s) contain cytarabine. Available strengths: 100 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled daunorubicin
3 marketed Canadian product(s) from 3 manufacturer(s) contain daunorubicin (daunorubicin hydrochloride). Available strengths: 20 MG, 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled decitabine and cedazuridine
1 marketed Canadian product(s) from 1 manufacturer(s) contain decitabine. Available strengths: 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled fludarabine
3 marketed Canadian product(s) from 3 manufacturer(s) contain fludarabine phosphate. Available strengths: 10 MG, 25 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled gemtuzumab
1 marketed Canadian product(s) from 1 manufacturer(s) contain gemtuzumab ozogamicin. Available strengths: 4.5 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled gemtuzumab ozogamicin
1 marketed Canadian product(s) from 1 manufacturer(s) contain gemtuzumab ozogamicin. Available strengths: 4.5 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled gilteritinib
1 marketed Canadian product(s) from 1 manufacturer(s) contain gilteritinib (gilteritinib fumarate). Available strengths: 40 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled melphalan
1 marketed Canadian product(s) from 1 manufacturer(s) contain melphalan. Available strengths: 2 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled melphalan for injection-hepatic delivery system
1 marketed Canadian product(s) from 1 manufacturer(s) contain melphalan. Available strengths: 2 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled quizartinib
2 marketed Canadian product(s) from 1 manufacturer(s) contain quizartinib (quizartinib hydrochloride). Available strengths: 17.7 MG, 26.5 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
Canadian-labelled venetoclax
3 marketed Canadian product(s) from 1 manufacturer(s) contain venetoclax. Available strengths: 10 MG, 100 MG, 50 MG. Because the comparator is registered in Canada, supply can be arranged without a Special Access request and with the Canadian label, package insert and lot documentation the protocol expects.
What we supply
- Canadian-labelled comparator sourced through licensed Canadian supply
- Certificate of Analysis for every batch
- Batch number and expiry documentation, with retained records
- Blinding-ready packaging and over-encapsulation on request
- 2–8 °C validated cold chain with temperature logging where required
- Health Canada Drug Establishment Licence #3-002896
Frequently asked questions
Can Nexara supply Canadian-labelled azacitidine as a trial comparator?
Yes. We source Canadian-marketed azacitidine under Health Canada Drug Establishment Licence #3-002896 and ship it with Certificate of Analysis, batch number and expiry documentation for use as a comparator or rescue supply in NCT05564390.
What documentation comes with each shipment?
Certificate of Analysis, manufacturer batch and expiry records, chain-of-custody documentation from the Canadian supply chain, and temperature records where cold chain applies. Blinding-ready packaging is available on request.
How long does comparator supply take?
Quotes are returned within one business day. Lead time depends on the presentation and the destination country's import route — typically 10 to 21 days once the importer's licence and any notification are in place.
Request comparator quote
Request comparator quote or call +1 (431) 588-9055.